Xeris Biopharma Holdings

ISIN US98422E1038

 | 

WKN A3C4ZC

Market cap (in EUR)
726 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 726 m
EPS, EUR -0.28
P/B ratio 110.0
P/E ratio -
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 188 m
Net income, EUR -51 m
Profit margin -27.00%

What ETF is Xeris Biopharma Holdings in?

There are 5 ETFs which contain Xeris Biopharma Holdings. All of these ETFs are listed in the table below. The ETF with the largest weighting of Xeris Biopharma Holdings is the L&G Pharma Breakthrough UCITS ETF.
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.08%
Equity
United States
Health Care
Biotech
23
iShares Nasdaq US Biotechnology UCITS ETF 0.08%
Equity
United States
Health Care
Biotech
454
Xtrackers Russell 2000 UCITS ETF 1C 0.03%
Equity
United States
Small Cap
1,332
SPDR Russell 2000 US Small Cap UCITS ETF 0.03%
Equity
United States
Small Cap
3,466
L&G Pharma Breakthrough UCITS ETF 3.33%
Equity
World
Health Care
Innovation
13

Order fees

Here you can find information about different brokers that allow you to trade stocks. Select your preferred order volume to compare the fees charged by the respective brokers.
 
Broker Rating Order fee Stock savings plans
0.99€
3000
View offer*
0.00€
1200
View offer*
1.00€
2500
View offer*
0.00€
2500
View offer*
0.00€
500
View offer*
Show all offers
Source: justETF Research; As of 7/2025; *Affiliate link
— The offers are sorted in the following way: 1. Rating 2. Order fee 3. Number of stock savings plans. The number of stock savings plans is rounded.
— No guarantee can be given for the completeness and correctness of the information listed. The information provided by the online brokers is decisive. In addition to the indicated broker fees, additional costs (e.g. spreads, gratuities and product costs) may apply.

Savings plan offers

Here you can find information about the savings plan availability for the stock. You can use the table to compare savings plan offers for the selected savings rate.
 
Broker Rating Execution fee Account fee
0.00€
0.00€
View offer*
1.50€
1.50%
0.00€
View offer*
Source: justETF Research; As of 7/2025; *Affiliate link
— The offers are sorted in the following way: 1. Rating 2. Execution fee 3. Number of stock savings plans. The number of stock savings plans is rounded.
— No guarantee can be given for the completeness and correctness of the information listed. The information provided by the online brokers is decisive. In addition to the indicated broker fees, additional costs (e.g. spreads, gratuities and product costs) may apply.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.